Plenary Keynote Session

TUESDAY, OCTOBER 5

Advancing Precision Immuno-Oncology

4:20 pm Plenary Keynote Introduction

Benjamin G. Neel, MD, PhD, Professor, Medicine, NYU Grossman School of Medicine; Director, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health


4:25 The Rapid Evolution of Precision IO: The Future Role of Biomarkers in IO Development in Clinical Utilization

Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany

As we turn the corner into a new decade, scientific and technological advances are helping to achieve a more precision approach for immunotherapy. While PD-L1 staining offers enrichment, mutation burden, microsatellite instability, and other immune biomarkers may be able to advance the precision approach. Evolution and real-world adaptation of testing tools, such as companion diagnostic capabilities, will become the new focal point to advance patient care.

4:55 Lessons Learned from BCMA and CD19 CAR-T Trials

Kristen M. Hege, MD, Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb

Dr. Hege will discuss drawing correlations between patient and product characteristics and clinical outcomes for iterative improvement; identifying variables associated with CAR-T expansion and persistence; understanding mechanisms and predictors of non-response, durable response and tumor escape; and new directions for cell therapy.

5:25 Immuno-Oncology Summit Connects


PLENARY KEYNOTE BIOGRAPHIES

Benjamin G. Neel, MD, PhD, Professor, Medicine, NYU Grossman School of Medicine; Director, Laura and Isaac Perlmutter Cancer Center, NYU Langone Health
Dr. Neel is the Director of the Laura and Isaac Perlmutter Cancer Center and Professor of Medicine at NYU Langone Health in New York City. His research focuses on cellular signaling, with a particular interest in the biology and regulation of protein-tyrosine kinases and protein-tyrosine phosphatases, the role and regulation of the RAS/ERK pathway in pancreas and lung cancer, and the biology of ovarian cancer. Dr. Neel earned his PhD in viral oncology from The Rockefeller University in 1982 and his MD from Cornell University Medical School the following year. His graduate work on oncogene (Myc) activation by slowly transforming RNA tumor viruses had major impact on the field. He previously held positions as the William B. Castle Chair of Medicine at Harvard Medical School and Director of Hematology-Oncology Research and Head of the Cancer Biology Program at Beth Israel Deaconess Medical Center, Boston, as Director of Research at Princess Margaret Cancer Center, and as Canada Research Chair and Professor of the Medical Biophysics at the University of Toronto, Ontario, Canada. Dr. Neel has authored >250 primary papers and 33 reviews, many in leading journals including Cell, Molecular Cell, Developmental Cell, Science, Nature, Nature Medicine and Nature Genetics. His work has been cited >50,000 times (h-index=117, i10=262). He is an elected member of the AAP, former Program Chair of the Annual Meeting and Member of Board of Directors of AACR, recipient of the initial Gertrude Elion Award of AACR and the Premier of Ontario Summit Award, and co-founded Northern Biologics, Navire Pharmaceuticals, and Jengu Therapeutics.

Zhen Su, MD, MBA, Senior Vice President, Head of Global Oncology Franchise, EMD Serono, a business of Merck KGaA, Darmstadt, Germany
Zhen Su, MD, MBA is Senior Vice President and Head of the Global Oncology Franchise for Merck (Merck KGaA, Darmstadt, Germany) / EMD Serono (the healthcare business of Merck in the US and Canada.) In this role, he leads the evolution of Merck Oncology into a biology-driven focused leader with market leadership globally in more than 60 countries. Dr. Su led the recent turnaround of the oncology franchise at Merck and grew the business above €1 Billion with double-digit growth annually while strategically shaping the future of the franchise and its exciting pipeline including recent global launches of BAVENCIO® (avelumab), and TEPMETKO® (Tepotinib). Building on a strong foundation of ERBITUX® (cetuximab) (outside the US and Canada), and newly marketed products, Merck Oncology has a strong commitment to the gastrointestinal, genitourinary and thoracic oncology communities with three innovation clusters: immuno-oncology, oncogenic pathways and DNA damage response.

Before taking on the commercial leadership, Dr. Su was the Chief Medical Officer of EMD Serono. In this role, he led the regional medical & clinical strategy across all therapeutic areas, including Neurology & Immunology, Oncology, Fertility and Endocrinology. Dr. Su joined Merck in 2015 as the Vice President and Head of US Medical for Oncology, and successfully built an Oncology Medical team from the ground up. Dr. Su was then appointed the Global Head of Medical Oncology, leading Oncology Medical activities globally to support marketed brands, product launches, and the acceleration of the oncology pipeline. Prior to joining Merck, Dr. Su held increasing leadership roles at Sanofi Oncology, where he led the taxane franchise, and at GSK Oncology, with a dedicated focus on GU oncology treatment development and commercialization.

A physician executive with 20 years of experience in Oncology, Dr. Su has strong clinical expertise in Oncology, Urology, and Immuno-Oncology. Prior to joining industry, Dr. Su held several academic positions, including Assistant Professor at Duke University Medical Center, where he also received his post-doctoral fellowship. He then served as Assistant Professor and Cancer Immunotherapy Program Director at the University of Florida. He also has more than 60 publications including journal articles and abstracts in the field of immuno-oncology and targeted therapy.

Dr. Su earned his MD from the Technical University of Dresden, Germany, and completed his MBA training at the University of Toronto, Canada.

Kristen M. Hege, MD, Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy, Bristol Myers Squibb
Dr. Hege is SVP, Early Clinical Development, Hematology/Oncology & Cell Therapy at Bristol Myers Squibb (BMS). Previously, she spent 10 years at Celgene where her team advanced a pipeline of small molecules, biologics and T cell therapies. She has led the bluebird-partnered BCMA CAR T cell program (ide-cel) in multiple myeloma from inception through FDA approval. Prior to joining Celgene, she held multiple executive roles at Cell Genesys, Cellerant, and Theraclone.

In addition to her work at BMS, Dr. Hege is a Clinical Professor of Medicine at UCSF where she continues to see patients with blood cancers weekly. Dr. Hege also serves on the Board of Directors of Mersana Therapeutics and was elected to the Board of Directors for the Society for Immunotherapy of Cancer (SITC) for a 3-year term from 2016-2019. Dr. Hege received her MD at UCSF and residency and hematology/oncology subspecialty training at Harvard and UCSF, respectively. In 2015, she was recognized by Fierce Biotech as one of the top 12 women in Biopharma. Her career path and long history with CAR T cell development was featured as part of the 25th anniversary celebration of Nature Medicine.


Final Agenda Available

Premier Sponsors

Agilent_New_Tagline

Biocytogen-2021